A-1 Ltd
A1LA-1 Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
The sharpest disagreement: annual EPS moved +300.0% against a +79.7% price move — the market has not yet caught up with the delivery.
The price is in a confirmed uptrend (65 weeks in) while the P/E sits at the 92nd percentile of its own 7-year range. Underneath, the last four quarters read deteriorating — profit −4.0% year on year, and 211% of the last 3 years' profit arrived as cash. What settles it: whether the price catches up with earnings that have already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
A-1 Ltd trades at ₹20.6, in a confirmed uptrend and 65 weeks into that stage. That is −30.2% against its own 200-day average. It sits at 15% of a 52-week range of ₹11 to ₹70. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (6 weeks and counting).
Today the stock is in a confirmed uptrend — week 65 of stage 2, confirmed. At ₹20.6 it trades −30.2% versus its 200-day average and sits at 15% of its 52-week range (₹11–₹70).
Against the market, two honest reads. Cumulative: over the last 7.4 years the stock moved +1,436% while the NIFTY 500 moved +157% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-01-23) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
A-1 Ltd trades at 383.0× P/E, at the pricey end of its own range (92nd percentile). Its long-run median P/E is 74.0×, measured across 7.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 383.0× is at the pricey end of its own range (92nd percentile), against a long-run median of 74.0× measured over 7.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +300.0% against a +79.7% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +64.5%/yr price move, ~+20.1%/yr came from earnings growth and ~+44.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
A-1 Ltd reads as deteriorating on its fundamental arc. Deteriorating — revenue and profit growth are shrinking (revenue growth −6.1% latest (single-quarter readings) against +78.0% at its 12-quarter best), ROCE holding at 11.0%. The read is built from 9 quarters across 3 curves, on partial evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +56.9% | +2.2% | +23.3% | +13.1% |
| Profit | +300.0% | −12.6% | +5.9% | — |
| EPS | +300.0% | −17.0% | +2.7% | +10.3% |
| Share price | +79.7% | +37.0% | +64.5% | — |
4-Factor Sector Score
41.0/100 — rank 52 of 52 in Trading · 50% evidence confidence · provisional, ranked below fully-evidenced peers
A-1 Ltd scores 41.0 out of 100 against the 52 companies it is compared with in Trading, ranking 52. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 16.2 + 10.7 + 8.8 + 5.3 = 41. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
A-1 Ltd reported ₹69.8 Cr of revenue in the Dec 25 quarter, −6.1% year on year. Over 10 years it has compounded at 13.1% a year. The last full year, FY25, came in at ₹331 Cr. The last four reported quarters add to ₹307 Cr.
FY25 revenue came in at ₹331 Cr (+56.9% on the year), capping 10 years at 13.1% compound. The latest quarter (Dec 25) printed ₹69.8 Cr, −6.1% year on year.
Pace check: the last four quarters averaged +11.5% growth against the decade's 13.1% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +8.3% over the last 4 quarters against +18.3%/yr over the last 8 — rolling over; TTM profit −30.6% vs +31.9%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
A-1 Ltd's operating margin is 2.9% in the Dec 25 quarter, −1.0 percentage points against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −4.0% to 6.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 2.9%, −1.0 pp against the same quarter a year ago. Across 11 fiscal years the operating margin has ranged −4.0%–6.0%.
🚨 Why the margin moved: operating margin went −1.0 pp year on year while gross margin went −0.8 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
A-1 Ltd earned ₹1.0 Cr of net profit in the Dec 25 quarter, −4.0% year on year. Full-year FY25 profit was ₹4.0 Cr. That is 1.4% of the quarter's revenue. The same quarter a year earlier earned ₹1.0 Cr. 1 of the last 12 reported quarters were loss-making.
Dec 25 profit was ₹1.0 Cr, −4.0% year on year. On the full year, FY25 printed ₹4.0 Cr (+300.0%).
🚨 Why profit moved: revenue contributed −6.1% and the margin −1.0 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit −28.4% vs revenue +11.5%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 211% of A-1 Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY25 that was ₹−11.0 Cr of operating cash against ₹4.0 Cr of profit. After ₹2.0 Cr of capital spending, ₹−13.0 Cr was left as free cash.
FY25: operating cash of ₹−11.0 Cr against reported profit of ₹4.0 Cr, leaving free cash of ₹−13.0 Cr after ₹2.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 211% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 211%: the cash cycle tightened 24 days between FY20 and FY25 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
A-1 Ltd's cash conversion cycle runs 57 days in FY25, down from 81 days in FY20. Capital spending ran ₹6.0 Cr over the last 3 years. At FY25 sales of ₹331 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹52.0 Cr sits inside the business at any moment.
FY25: debtors at 56 days, inventory at 3 days — roughly 0.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 57 days, tighter than FY20's 81.
The full loop: cash goes out to suppliers and production on day 0; stock waits 3 days to sell; customers pay about 56 days after that; and suppliers themselves are paid at 2 days — netting out to the 57-day cycle.
In money terms: at FY25 sales of ₹331 Cr, each day of the cycle holds about ₹0.9 Cr — so the 57-day loop keeps roughly ₹52.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹6.0 Cr over the last 3 fiscal years against ₹12.0 Cr of depreciation — spending at or below maintenance level. Capital work-in-progress stands at ₹0.0 Cr (FY25) — capacity paid for but not yet earning.
The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
A-1 Ltd earns a ROCE of 11% in FY25. That is up from a trough of 4% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 1.2% net margin on 4.47× asset turns.
FY25 ROCE is 11%, recovered from a FY24 trough of 4% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 1.2% net margin × 4.47× asset turns × 1.48× balance-sheet leverage ≈ 7.9% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
A-1 Ltd carries ₹22.0 Cr of borrowings against ₹50.0 Cr of equity in FY25, a debt-to-equity of 0.44. Operating profit covers the interest bill 5×. Over 5 years borrowings went from ₹6.0 Cr to ₹22.0 Cr. Capital spending ran ₹6.0 Cr across the last 3 of those years.
FY25: borrowings of ₹22.0 Cr against equity of ₹50.0 Cr — a debt-to-equity of 0.44. Operating profit covers the interest bill 5×. Over 5 years borrowings went from ₹6.0 Cr to ₹22.0 Cr while capital spending ran ₹6.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Foreign institutions added 3.8 points of A-1 Ltd over 8 quarters, the biggest move on the register. That takes foreign institutions to 6.7% of the company. Domestic institutions moved +0.1 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Foreign institutions: +3.8 points over 8 quarters to 6.7%; Domestic institutions: +0.1 points over 8 quarters to 0.1%; Promoters: +0.0 points over 8 quarters to 70.0%.
Why the register moved: foreign institutions drove it (+3.8 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
A-1 Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Onix Solar Energy LtdONIXSOLAR | 70.9/100Favorable setup69% evidence | 28.9/35 Revenue 26.2% · PAT 100% · OPM change 23 pp 95% evidence | 18.3/25 ROCE 32% · OPM 30% 76% evidence | 10.3/20 P/E 24.4× · PEG — 15% evidence | 13.4/20 RS sector 68.4% · RS bench -3.5% · 1Y 49.1%12 of 12 weeks ahead 70% evidence | |
| Exact sum: 28.9 + 18.3 + 10.3 + 13.4 = 70.9 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Rashi Peripherals LtdRPTECH | 69.0/100Favorable setup75% evidence | LEADER | 24.9/35 Revenue 40.4% · PAT 50.2% · OPM change -0.3 pp 95% evidence | 14.7/25 ROCE 17% · OPM 3% 76% evidence | 10.7/20 P/E 17.1× · PEG — 15% evidence | 18.7/20 RS sector 51.6% · RS bench 69.1% · 1Y 176.9%12 of 12 weeks ahead 100% evidence |
| Exact sum: 24.9 + 14.7 + 10.7 + 18.7 = 69 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Nupur Recyclers LtdNRL | 67.9/100Favorable setup87% evidence | LEADER | 22.5/35 Revenue 40.6% · PAT 29.8% · OPM change 3.6 pp 95% evidence | 16.5/25 ROCE 15.1% · OPM 11.6% 95% evidence | 9.2/20 P/E 53.6× · PEG — 50% evidence | 19.7/20 RS sector 66.4% · RS bench 88.4% · 1Y 89.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.5 + 16.5 + 9.2 + 19.7 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Magnus Steel & Infra Ltd517320 | 67.5/100Thin evidence · provisional56% evidence | 27.8/35 Revenue 100% · PAT 100% · OPM change 1.6 pp 83% evidence | 18.5/25 ROCE 171% · OPM 21.3% 76% evidence | 9.2/20 P/E 92.5× · PEG — 15% evidence | 12.0/20 RS sector — · RS bench 46.1% · 1Y 1449.6%0 of 1 week ahead to 2026-06-28 25% evidence | |
| Exact sum: 27.8 + 18.5 + 9.2 + 12 = 67.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 5Vision Infra Equipment Solutions LtdVIESL | 67.3/100Thin evidence · provisional56% evidence | TURNING | 19.0/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 19.8/25 ROCE 22.6% · OPM 26% 95% evidence | 10.9/20 P/E 14.9× · PEG — 15% evidence | 17.6/20 RS sector 26.9% · RS bench 44.5% · 1Y 122.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 19 + 19.8 + 10.9 + 17.6 = 67.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 6Shankara Buildpro LtdBUILDPRO | 63.3/100Mixed-positive evidence63% evidence | BREAKING OUT | 25.6/35 Revenue 26.3% · PAT 41.9% · OPM change -0.2 pp 100% evidence | 17.3/25 ROCE 39% · OPM 3.2% 100% evidence | 10.4/20 P/E 22.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 12 weeks ahead 0% evidence |
| Exact sum: 25.6 + 17.3 + 10.4 + 10 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Ivalue Infosolutions LtdIVALUE | 60.4/100Mixed-positive evidence60% evidence | ASLEEP | 20.6/35 Revenue 5.4% · PAT 22.1% · OPM change 5.6 pp 95% evidence | 18.6/25 ROCE 25.4% · OPM 10% 95% evidence | 11.2/20 P/E 11.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -19.4%6 of 10 weeks ahead 0% evidence |
| Exact sum: 20.6 + 18.6 + 11.2 + 10 = 60.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Sudarshan Pharma Industries Ltd543828 | 60.3/100Mixed-positive evidence82% evidence | LEADER | 20.9/35 Revenue 32.9% · PAT 24.3% · OPM change 1.5 pp 95% evidence | 13.6/25 ROCE 15.1% · OPM 9.1% 76% evidence | 8.9/20 P/E 39.2× · PEG — 50% evidence | 16.9/20 RS sector 17.5% · RS bench 33.4% · 1Y 25.2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.6 + 8.9 + 16.9 = 60.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Euro Pratik Sales LtdEUROPRATIK | 59.9/100Mixed-positive evidence73% evidence | ASLEEP | 15.1/35 Revenue 23.9% · PAT 29% · OPM change -8 pp 100% evidence | 19.5/25 ROCE 38.4% · OPM 26% 100% evidence | 15.3/20 P/E 29.1× · PEG 0.62 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y 4.7%6 of 10 weeks ahead 0% evidence |
| Exact sum: 15.1 + 19.5 + 15.3 + 10 = 59.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 10Tembo Global Industries LtdTEMBO | 59.0/100Mixed-positive evidence80% evidence | TURNING | 22.2/35 Revenue 34% · PAT 55.7% · OPM change 5 pp 95% evidence | 18.4/25 ROCE 22.8% · OPM 16% 95% evidence | 11.3/20 P/E 10.2× · PEG — 15% evidence | 7.1/20 RS sector -17.4% · RS bench -4.5% · 1Y -10.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 22.2 + 18.4 + 11.3 + 7.1 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Mangalam Global Enterprise LtdMGEL | 58.7/100Mixed-positive evidence80% evidence | 25.7/35 Revenue 41.4% · PAT 100% · OPM change 0.5 pp 95% evidence | 15.8/25 ROCE 17% · OPM 1.9% 95% evidence | 11.1/20 P/E 13× · PEG — 15% evidence | 6.1/20 RS sector -14.5% · RS bench -0.2% · 1Y -3.5%6 of 7 weeks ahead to 2026-08-09 100% evidence | |
| Exact sum: 25.7 + 15.8 + 11.1 + 6.1 = 58.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -14.5% and the one-year return is -3.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Arisinfra Solutions LtdARIS | 57.6/100Mixed-positive evidence65% evidence | TURNING | 22.0/35 Revenue 45.3% · PAT 100% · OPM change 2 pp 95% evidence | 15.1/25 ROCE 15.6% · OPM 11% 95% evidence | 10.8/20 P/E 15.5× · PEG — 15% evidence | 9.7/20 RS sector — · RS bench -1.2% · 1Y -12.3%4 of 10 weeks ahead 25% evidence |
| Exact sum: 22 + 15.1 + 10.8 + 9.7 = 57.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Aayush Art and Bullion Ltd540718 | 56.4/100Thin evidence · provisional54% evidence | BREAKING OUT | 21.2/35 Revenue 100% · PAT — · OPM change 1.6 pp 35% evidence | 13.2/25 ROCE 18.9% · OPM 6% 76% evidence | 8.9/20 P/E 245× · PEG — 15% evidence | 13.1/20 RS sector -1.1% · RS bench 13.5% · 1Y 29.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 13.2 + 8.9 + 13.1 = 56.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 14Patel Retail LtdPATELRMART | 53.8/100Mixed-positive evidence65% evidence | ASLEEP | 18.1/35 Revenue 42.3% · PAT 59.7% · OPM change -2.2 pp 95% evidence | 14.3/25 ROCE 15.3% · OPM 6.1% 95% evidence | 10.8/20 P/E 16.9× · PEG — 15% evidence | 10.6/20 RS sector — · RS bench 2.8% · 1Y -18.4%5 of 10 weeks ahead 25% evidence |
| Exact sum: 18.1 + 14.3 + 10.8 + 10.6 = 53.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Prostarm Info Systems LtdPROSTARM | 52.0/100Mixed-positive evidence65% evidence | BASING | 17.1/35 Revenue 30.5% · PAT 19.1% · OPM change 1.4 pp 95% evidence | 16.1/25 ROCE 18% · OPM 8.5% 95% evidence | 10.5/20 P/E 22× · PEG — 15% evidence | 8.3/20 RS sector — · RS bench -12.2% · 1Y -35.5%0 of 10 weeks ahead 25% evidence |
| Exact sum: 17.1 + 16.1 + 10.5 + 8.3 = 52 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Fabtech Technologies LtdFABTECH | 50.8/100Thin evidence · provisional52% evidence | TURNING | 17.5/35 Revenue 14.2% · PAT 41% · OPM change 14.8 pp 71% evidence | 12.3/25 ROCE 13.6% · OPM 5.7% 95% evidence | 11.0/20 P/E 13.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 10 weeks ahead 0% evidence |
| Exact sum: 17.5 + 12.3 + 11 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 17Lloyds Enterprises LtdLLOYDSENT | 50.3/100Mixed-positive evidence75% evidence | TURNING | 18.1/35 Revenue 33% · PAT -21.4% · OPM change 9 pp 95% evidence | 11.3/25 ROCE 3.7% · OPM 16% 76% evidence | 9.1/20 P/E 93.3× · PEG — 15% evidence | 11.8/20 RS sector -5% · RS bench 8.7% · 1Y -6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 11.3 + 9.1 + 11.8 = 50.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18BMW Ventures LtdBMW | 50.0/100Thin evidence · provisional55% evidence | 16.9/35 Revenue 18.5% · PAT 24.2% · OPM change -0.6 pp 95% evidence | 11.9/25 ROCE 12% · OPM 3.4% 76% evidence | 11.2/20 P/E 12.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -18.7%0 of 10 weeks ahead 0% evidence | |
| Exact sum: 16.9 + 11.9 + 11.2 + 10 = 50 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19SG Mart LtdSGMART | 48.9/100Mixed-negative evidence93% evidence | LEADER | 13.9/35 Revenue 10.4% · PAT 14.7% · OPM change 1.4 pp 100% evidence | 8.6/25 ROCE 10.2% · OPM 4.5% 100% evidence | 8.2/20 P/E 76.1× · PEG 1.92 65% evidence | 18.2/20 RS sector 34.9% · RS bench 51.7% · 1Y 106.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 8.6 + 8.2 + 18.2 = 48.9 · Decision use: Price leads the evidence: RS versus the benchmark is 51.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20Bizotic Commercial Ltd543926 | 48.7/100Thin evidence · provisional58% evidence | BASING | 19.8/35 Revenue — · PAT — · OPM change 0 pp 26% evidence | 18.6/25 ROCE 26.8% · OPM 8% 76% evidence | 9.7/20 P/E 34.1× · PEG — 50% evidence | 0.6/20 RS sector -86.7% · RS bench -18.3% · 1Y -72.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 18.6 + 9.7 + 0.6 = 48.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21Yogi LtdYOGI | 47.9/100Thin evidence · provisional58% evidence | 20.3/35 Revenue 97.5% · PAT 68.1% · OPM change -5.9 pp 62% evidence | 9.9/25 ROCE 12.8% · OPM 2.6% 76% evidence | 9.5/20 P/E 54.1× · PEG — 15% evidence | 8.2/20 RS sector -6.5% · RS bench -2.1% · 1Y -11.1%2 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.3 + 9.9 + 9.5 + 8.2 = 47.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Shiv Aum Steels LtdSHIVAUM | 47.4/100Thin evidence · provisional55% evidence | BREAKING OUT | 16.9/35 Revenue — · PAT — · OPM change 1.3 pp 45% evidence | 11.4/25 ROCE 8% · OPM 4.7% 95% evidence | 7.2/20 P/E 66.8× · PEG — 50% evidence | 11.9/20 RS sector — · RS bench 38.3% · 1Y —6 of 6 weeks ahead 25% evidence |
| Exact sum: 16.9 + 11.4 + 7.2 + 11.9 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Dhunseri Ventures LtdDVL | 46.8/100Mixed-negative evidence87% evidence | BREAKING OUT | 12.6/35 Revenue -20% · PAT 31.7% · OPM change -12 pp 95% evidence | 9.7/25 ROCE 6.7% · OPM 39% 95% evidence | 11.9/20 P/E 5.3× · PEG — 50% evidence | 12.6/20 RS sector -7.1% · RS bench 8% · 1Y -14.9%7 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.7 + 11.9 + 12.6 = 46.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Adani Enterprises LtdADANIENT | 45.5/100Mixed-negative evidence93% evidence | TURNING | 14.3/35 Revenue 18.1% · PAT 4.2% · OPM change 0 pp 100% evidence | 8.5/25 ROCE 5.8% · OPM 15% 100% evidence | 7.7/20 P/E 174× · PEG 1.96 65% evidence | 15.0/20 RS sector 8.6% · RS bench 23.9% · 1Y 38.4%10 of 12 weeks ahead 100% evidence |
| Exact sum: 14.3 + 8.5 + 7.7 + 15 = 45.5 · Decision use: Price leads the evidence: RS versus the benchmark is 23.9%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 25MMTC LtdMMTC | 44.8/100Mixed-negative evidence96% evidence | ASLEEP | 15.1/35 Revenue 0% · PAT 100% · OPM change -1270 pp 100% evidence | 8.0/25 ROCE 8.7% · OPM — 84% evidence | 15.3/20 P/E 46.1× · PEG 0.92 100% evidence | 6.4/20 RS sector -14.9% · RS bench -1.9% · 1Y -4.1%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15.1 + 8 + 15.3 + 6.4 = 44.8 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 26State Trading Corporation of India LtdSTCINDIA | 42.5/100Mixed-negative evidence67% evidence | ASLEEP | 19.6/35 Revenue — · PAT 100% · OPM change -14.6 pp 67% evidence | 5.6/25 ROCE -0.9% · OPM — 80% evidence | 11.9/20 P/E 14× · PEG — 50% evidence | 5.4/20 RS sector -28.7% · RS bench -5.6% · 1Y -5.6%2 of 11 weeks ahead 70% evidence |
| Exact sum: 19.6 + 5.6 + 11.9 + 5.4 = 42.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 27RRP Semiconductor LtdRRP | 41.1/100Thin evidence · provisional54% evidence | 11.4/35 Revenue -80% · PAT -80% · OPM change 3.3 pp 71% evidence | 5.4/25 ROCE -32.7% · OPM — 61% evidence | 10.0/20 P/E — · PEG — 0% evidence | 14.3/20 RS sector 65.3% · RS bench 0.8% · 1Y 66.5%0 of 1 week ahead 70% evidence | |
| Exact sum: 11.4 + 5.4 + 10 + 14.3 = 41.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 28Cropster Agro Ltd523105 | 40.7/100Mixed-negative evidence65% evidence | 16.0/35 Revenue 28.4% · PAT 6.5% · OPM change 2.1 pp 83% evidence | 11.3/25 ROCE 12.4% · OPM 8.7% 76% evidence | 10.1/20 P/E 31× · PEG — 15% evidence | 3.3/20 RS sector -72.7% · RS bench -62.7% · 1Y -83.2%0 of 1 week ahead to 2026-08-09 70% evidence | |
| Exact sum: 16 + 11.3 + 10.1 + 3.3 = 40.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Hexa Tradex LtdHEXATRADEX | 40.3/100Mixed-negative evidence65% evidence | BASING | 17.2/35 Revenue 0.4% · PAT 70.3% · OPM change 13.6 pp 71% evidence | 6.1/25 ROCE -0.1% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 7.0/20 RS sector -16.8% · RS bench -3.7% · 1Y -12.7%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 6.1 + 10 + 7 = 40.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Hardwyn India LtdHARDWYN | 40.2/100Mixed-negative evidence87% evidence | ASLEEP | 13.8/35 Revenue 2.6% · PAT -8.5% · OPM change -0.2 pp 95% evidence | 12.5/25 ROCE 4.8% · OPM 13% 95% evidence | 12.1/20 P/E 50.6× · PEG — 50% evidence | 1.8/20 RS sector -38.3% · RS bench -29.5% · 1Y -3.4%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 12.5 + 12.1 + 1.8 = 40.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 31Blue Pearl Agriventures LtdBPAGRI | 39.8/100Mixed-negative evidence69% evidence | 20.5/35 Revenue 19.3% · PAT 59.1% · OPM change 0.3 pp 95% evidence | 6.3/25 ROCE 2.2% · OPM 3.3% 76% evidence | 8.7/20 P/E 514× · PEG — 15% evidence | 4.3/20 RS sector -33.5% · RS bench -82.5% · 1Y -91.2%1 of 12 weeks ahead 70% evidence | |
| Exact sum: 20.5 + 6.3 + 8.7 + 4.3 = 39.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 32Pervasive Commodities Ltd517172 | 38.3/100Thin evidence · provisional52% evidence | 12.7/35 Revenue 25.6% · PAT -8.3% · OPM change -6.1 pp 95% evidence | 5.6/25 ROCE 0% · OPM -10.2% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.0/20 RS sector — · RS bench — · 1Y — 0% evidence | |
| Exact sum: 12.7 + 5.6 + 10 + 10 = 38.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 33Riddhi Siddhi Gluco Biols Ltd524480 | 38.0/100Mixed-negative evidence82% evidence | FADING | 12.4/35 Revenue -38% · PAT 38.4% · OPM change -2.8 pp 95% evidence | 6.6/25 ROCE 2.7% · OPM -3% 76% evidence | 6.5/20 P/E 37.3× · PEG — 50% evidence | 12.5/20 RS sector 10.5% · RS bench 25.4% · 1Y 33.5%9 of 12 weeks ahead 100% evidence |
| Exact sum: 12.4 + 6.6 + 6.5 + 12.5 = 38 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 34PTC India LtdPTC | 36.6/100Mixed-negative evidence82% evidence | BASING | 11.2/35 Revenue 13.3% · PAT -43.1% · OPM change -3.9 pp 95% evidence | 12.6/25 ROCE 13.4% · OPM 3.1% 76% evidence | 9.7/20 P/E 8.8× · PEG — 50% evidence | 3.1/20 RS sector -21.6% · RS bench -9.8% · 1Y -13%0 of 12 weeks ahead 100% evidence |
| Exact sum: 11.2 + 12.6 + 9.7 + 3.1 = 36.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 35Neueon Corporation LtdNEUEON | 35.6/100Thin evidence · provisional59% evidence | ASLEEP | 9.1/35 Revenue 17.8% · PAT -80% · OPM change -1039 pp 71% evidence | 3.7/25 ROCE -40.4% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 12.8/20 RS sector 12.7% · RS bench -1.5% · 1Y —1 of 12 weeks ahead 70% evidence |
| Exact sum: 9.1 + 3.7 + 10 + 12.8 = 35.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 36Kothari Industrial Corporation LtdKOTIC | 34.2/100Adverse evidence63% evidence | BASING | 18.8/35 Revenue 75.9% · PAT -80% · OPM change -41.8 pp 71% evidence | 1.6/25 ROCE -28.9% · OPM -43% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.8/20 RS sector -58.6% · RS bench -43.5% · 1Y -77.5%0 of 9 weeks ahead 70% evidence |
| Exact sum: 18.8 + 1.6 + 10 + 3.8 = 34.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 37Shanti Overseas (India) LtdSHANTI | 32.3/100Thin evidence · provisional56% evidence | 11.2/35 Revenue -63.4% · PAT 100% · OPM change -200.5 pp 40% evidence | 4.5/25 ROCE -25.2% · OPM -216.5% 71% evidence | 13.1/20 P/E 3× · PEG — 50% evidence | 3.5/20 RS sector -60.4% · RS bench -49.7% · 1Y -47.1%0 of 12 weeks ahead to 2026-03-29 70% evidence | |
| Exact sum: 11.2 + 4.5 + 13.1 + 3.5 = 32.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 38BN Agrochem LtdBNAGROCHEM | 32.2/100Adverse evidence77% evidence | ASLEEP | 12.9/35 Revenue 84.5% · PAT -61% · OPM change -9.4 pp 100% evidence | 4.4/25 ROCE 4.4% · OPM 2.3% 100% evidence | 9.0/20 P/E 117× · PEG — 15% evidence | 5.9/20 RS sector -16.7% · RS bench -35.6% · 1Y -46.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 12.9 + 4.4 + 9 + 5.9 = 32.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 39Uniphos Enterprises LtdUNIENTER | 30.4/100Adverse evidence69% evidence | BASING | 12.6/35 Revenue -77.1% · PAT 100% · OPM change -0.9 pp 71% evidence | 4.6/25 ROCE 0.8% · OPM — 80% evidence | 8.8/20 P/E 31.4× · PEG — 50% evidence | 4.4/20 RS sector -43.6% · RS bench -22% · 1Y -41%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 4.6 + 8.8 + 4.4 = 30.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 40Oswal Agro Mills LtdOSWALAGRO | 24.7/100Adverse evidence67% evidence | 2.8/35 Revenue -80% · PAT -80% · OPM change -21782.3 pp 95% evidence | 7.8/25 ROCE 2% · OPM — 80% evidence | 10.0/20 P/E — · PEG — 0% evidence | 4.1/20 RS sector -50.3% · RS bench -32% · 1Y -49.6%0 of 6 weeks ahead to 2026-08-16 70% evidence | |
| Exact sum: 2.8 + 7.8 + 10 + 4.1 = 24.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 41Mardia Samyoung Capillary Tubes Company LtdMSCTC | 56.9/100Thin evidence · provisional32% evidence | 20.8/35 Revenue 100% · PAT 100% · OPM change — 29% evidence | 15.2/25 ROCE 22.6% · OPM 15.3% 57% evidence | 8.6/20 P/E 687× · PEG — 15% evidence | 12.3/20 RS sector — · RS bench 74.6% · 1Y 93.7%6 of 12 weeks ahead to 2026-03-08 25% evidence | |
| Exact sum: 20.8 + 15.2 + 8.6 + 12.3 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 42Proventus Agrocom LtdPROV | 56.7/100Thin evidence · provisional48% evidence | BREAKING OUT | 19.6/35 Revenue — · PAT — · OPM change 0.2 pp 26% evidence | 12.4/25 ROCE 11.5% · OPM 1.8% 95% evidence | 13.1/20 P/E 42.8× · PEG — 50% evidence | 11.6/20 RS sector — · RS bench 26.9% · 1Y —12 of 12 weeks ahead 25% evidence |
| Exact sum: 19.6 + 12.4 + 13.1 + 11.6 = 56.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 43DC Infotech & Communication LtdDCI | 56.3/100Thin evidence · provisional35% evidence | 18.6/35 Revenue — · PAT — · OPM change 0.3 pp 24% evidence | 17.6/25 ROCE 22.9% · OPM 4.7% 76% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 9.5/20 RS sector — · RS bench -1.6% · 1Y — 25% evidence | |
| Exact sum: 18.6 + 17.6 + 10.6 + 9.5 = 56.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 44SK Minerals & Additives Ltd544584 | 55.8/100Thin evidence · provisional36% evidence | TURNING | 16.6/35 Revenue — · PAT — · OPM change 1.3 pp 39% evidence | 19.0/25 ROCE 26.2% · OPM 10.7% 76% evidence | 10.2/20 P/E 29.5× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —3 of 4 weeks ahead 0% evidence |
| Exact sum: 16.6 + 19 + 10.2 + 10 = 55.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 45Monika Alcobev LtdMONIKA | 54.0/100Thin evidence · provisional22% evidence | 16.4/35 Revenue — · PAT — · OPM change -2 pp 15% evidence | 17.0/25 ROCE 21% · OPM 15% 57% evidence | 10.6/20 P/E 20.4× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -10.9%0 of 12 weeks ahead to 2026-03-08 0% evidence | |
| Exact sum: 16.4 + 17 + 10.6 + 10 = 54 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 46Shah Foods Ltd519031 | 53.6/100Thin evidence · provisional18% evidence | TURNING | 17.1/35 Revenue — · PAT — · OPM change -10.7 pp 7% evidence | 15.3/25 ROCE — · OPM 18% 30% evidence | 8.8/20 P/E 276× · PEG — 15% evidence | 12.4/20 RS sector — · RS bench 103.9% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 17.1 + 15.3 + 8.8 + 12.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 47Pramara Promotions LtdPRAMARA | 51.7/100Thin evidence · provisional47% evidence | 16.6/35 Revenue — · PAT — · OPM change -1 pp 15% evidence | 13.9/25 ROCE 15.2% · OPM 15% 71% evidence | 6.9/20 P/E 51.3× · PEG — 50% evidence | 14.3/20 RS sector 7.9% · RS bench 29% · 1Y 34.5%10 of 12 weeks ahead to 2026-04-19 70% evidence | |
| Exact sum: 16.6 + 13.9 + 6.9 + 14.3 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 48Manbro Industries Ltd512595 | 50.9/100Thin evidence · provisional22% evidence | 18.3/35 Revenue — · PAT — · OPM change 32.8 pp 5% evidence | 13.1/25 ROCE — · OPM 6.6% 23% evidence | 10.0/20 P/E — · PEG — 0% evidence | 9.5/20 RS sector -17.3% · RS bench 37.2% · 1Y 62.6%12 of 12 weeks ahead to 2026-05-03 70% evidence | |
| Exact sum: 18.3 + 13.1 + 10 + 9.5 = 50.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 49Le Merite Exports LtdLEMERITE | 47.2/100Thin evidence · provisional40% evidence | 18.9/35 Revenue — · PAT — · OPM change 0.9 pp 15% evidence | 9.1/25 ROCE 8.6% · OPM 2.8% 71% evidence | 9.3/20 P/E 87× · PEG — 15% evidence | 9.9/20 RS sector -9% · RS bench 15% · 1Y 28.1%2 of 12 weeks ahead to 2026-05-17 70% evidence | |
| Exact sum: 18.9 + 9.1 + 9.3 + 9.9 = 47.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 50Satani Bearings Ltd505703 | 45.2/100Thin evidence · provisional38% evidence | TURNING | 20.5/35 Revenue — · PAT 100% · OPM change — 33% evidence | 4.7/25 ROCE 1% · OPM -3.7% 76% evidence | 8.6/20 P/E 5197× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 24.9% · 1Y 176.6%1 of 11 weeks ahead 25% evidence |
| Exact sum: 20.5 + 4.7 + 8.6 + 11.4 = 45.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 51Keto Motors Ltd537392 | 43.3/100Thin evidence · provisional38% evidence | TURNING | 16.3/35 Revenue — · PAT 100% · OPM change — 33% evidence | 6.0/25 ROCE -0.3% · OPM 10.7% 76% evidence | 8.5/20 P/E 7503× · PEG — 15% evidence | 12.5/20 RS sector — · RS bench 272.8% · 1Y —4 of 4 weeks ahead 25% evidence |
| Exact sum: 16.3 + 6 + 8.5 + 12.5 = 43.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 52A-1 Ltdthis pageA1L | 41.0/100Thin evidence · provisional50% evidence | 16.2/35 Revenue 8.3% · PAT -30.6% · OPM change -0.9 pp 53% evidence | 10.7/25 ROCE 10.6% · OPM 2.9% 57% evidence | 8.8/20 P/E 383× · PEG — 15% evidence | 5.3/20 RS sector -24.5% · RS bench -16% · 1Y -8.6%6 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 16.2 + 10.7 + 8.8 + 5.3 = 41 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is A-1 Ltd's share price today?
A-1 Ltd trades at ₹20.6, +79.7% over the past year. The company is valued at ₹947 Cr. The stock sits at 15% of its 52-week range of ₹11–₹70, −30.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 65 weeks in. — as of 11 September 2026.
What were A-1 Ltd's latest quarterly results?
A-1 Ltd reported revenue of ₹69.8 Cr and net profit of ₹1.0 Cr for the Dec 25 quarter. Revenue fell 6.1% and profit fell 4.0% year on year. Earnings per share were ₹0.02. The operating margin was 2.9%, 1.0 pp lower than a year earlier. — as of 11 September 2026.
What is A-1 Ltd's revenue?
A-1 Ltd reported revenue of ₹69.8 Cr in the Dec 25 quarter, −6.1% year on year. For the full FY25 fiscal year, revenue was ₹331 Cr (+56.9%). Over the last 10 years revenue compounded at 13.1% a year. — as of 11 September 2026.
What is A-1 Ltd's profit?
A-1 Ltd earned ₹1.0 Cr of net profit in the Dec 25 quarter, −4.0% year on year. Full-year FY25 profit was ₹4.0 Cr. The operating margin ran 2.9% in the latest quarter. — as of 11 September 2026.
What is A-1 Ltd's market cap?
A-1 Ltd's market capitalisation is ₹947 Cr at a share price of ₹20.6. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is A-1 Ltd's P/E ratio?
A-1 Ltd trades at a P/E of 383.0×, at the 92nd percentile of its own 7-year range, against a long-run median of 74.0×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does A-1 Ltd pay a dividend?
Yes — A-1 Ltd's dividend payout was 47% of profit in FY25, and it recorded a payout in 5 of its last 11 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 11 September 2026.
Is A-1 Ltd overvalued?
On its own history, A-1 Ltd looks expensive: its P/E of 383.0× sits at the 92nd percentile of its 7-year range (long-run median 74.0×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 11 September 2026.
Is A-1 Ltd growing?
Not right now — A-1 Ltd's latest numbers are shrinking: latest-quarter revenue −6.1% year on year, profit −4.0%, and the margin −1.0 pp at 2.9%. The earnings engine currently reads: deteriorating — as of 11 September 2026.
How is A-1 Ltd performing?
A-1 Ltd is in a confirmed uptrend, 65 weeks in. Its latest quarter's revenue fell 6.1% and profit fell 4.0% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 6 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
What stage is A-1 Ltd in?
Deteriorating — revenue and profit growth are shrinking (revenue growth −6.1% latest (single-quarter readings) against +78.0% at its 12-quarter best), ROCE holding at 11.0%. The read comes from the last 12 quarters of growth (revenue growth −6.1% latest, profit growth −4.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 11 September 2026.
Is A-1 Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 65 of stage 2), trading −30.2% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is A-1 Ltd beating the market?
Not lately — on a trailing-13-week view A-1 Ltd is currently behind the NIFTY 500 (6 weeks and counting; last ahead the week of 2026-01-23), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 7.4 years the stock moved +1,436% against the NIFTY 500's +157% — ahead of the index over the full window. — as of 11 September 2026.
Will A-1 Ltd's share price go up?
This page publishes no price forecast for A-1 Ltd. What it measures instead: the share price is ₹20.6, the price is in a confirmed uptrend 65 weeks in. Its P/E of 383.0× sits at the 92nd percentile of its own 7-year range. — as of 11 September 2026.
Who owns A-1 Ltd?
Promoters hold 70.0% of A-1 Ltd, foreign institutions 6.7%, domestic institutions 0.1% and the public 23.2% (latest quarter). The biggest move on the register over the last two years: Foreign institutions added 3.8 points over 8 quarters. — as of 11 September 2026.
Does A-1 Ltd have too much debt?
It is moderate — A-1 Ltd's debt-to-equity is 0.44, and operating profit covers the interest bill 5×. FY25 borrowings were ₹22.0 Cr against equity of ₹50.0 Cr. Read the returns on this page with that leverage in mind — as of 11 September 2026.
What is A-1 Ltd's capex?
A-1 Ltd spent ₹6.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was ₹2.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is A-1 Ltd's cash flow?
A-1 Ltd consumed ₹11.0 Cr of operating cash in FY25 — cash flowed out rather than in (free cash flow: ₹−13.0 Cr). Operating cash was negative while the company reported a profit of ₹4.0 Cr. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is A-1 Ltd's profit real cash?
Yes — over the last 3 fiscal years, 211% of A-1 Ltd's reported profit arrived as operating cash. Though the latest year ran at -275% — the trend is the thing to watch. In FY25, operating cash was ₹−11.0 Cr against reported profit of ₹4.0 Cr. The cash then goes into a mix of the working-capital cycle and capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is A-1 Ltd in its business cycle?
A-1 Ltd's FY25 operating margin was 3.0%, against a 11-year band of −4.0%–6.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 2.9%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the A-1 Ltd story?
The sharpest disagreement: annual EPS moved +300.0% against a +79.7% price move — the market has not yet caught up with the delivery. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is A-1 Ltd a stock worth studying right now?
This is not investment advice. The machine read: A-1 Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: whether the price catches up with earnings that have already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!